Role of Non-Coding Rnas in the Response of Glioblastoma to Temozolomide Publisher Pubmed



Goleij P^{1, 2} ; Pourali G³ ; Raisi A^{4, 5} ; Ravaei F^{4, 5} ; Golestan S⁶ ; Abed A⁷ ; Razavi ZS^{4, 5} ; Zarepour F^{4, 5} ; Taghavi SP^{4, 5} ; Ahmadi Asouri S⁸ ; Rafiei M^{4, 5} ; Mousavi SM⁹ ; Hamblin MR¹⁰ ; Talei S¹¹ Show All Authors Show Affiliations
Source: Molecular Neurobiology Published:2025

Abstract

Chemotherapy and radiotherapy are widely used in clinical practice across the globe as cancer treatments. Intrinsic or acquired chemoresistance poses a significant problem for medical practitioners and researchers, causing tumor recurrence and metastasis. The most dangerous kind of malignant brain tumor is called glioblastoma multiforme (GBM) that often recurs following surgery. The most often used medication for treating GBM is temozolomide chemotherapy; however, most patients eventually become resistant. Researchers are studying preclinical models that accurately reflect human disease and can be used to speed up drug development to overcome chemoresistance in GBM. Non-coding RNAs (ncRNAs) have been shown to be substantial in regulating tumor development and facilitating treatment resistance in several cancers, such as GBM. In this work, we mentioned the mechanisms of how different ncRNAs (microRNAs, long non-coding RNAs, circular RNAs) can regulate temozolomide chemosensitivity in GBM. We also address the role of these ncRNAs encapsulated inside secreted exosomes. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.